Bristol-myers Squibb Compnay

Bin Chen

Libing Chen

James Aaron Balog

Audris Huang

Amy C Hart

William R Ewing

Ashvinikumar V Gavai

Wayne D Vaccaro

Brian E Fink

John S Tokarski

Steven P Seitz

Yong Zhang

Bruce A Ellsworth

Weifang Shan

Yufen Zhao

Liqi He

Kurt Zimmermann

Harold A Mastalerz

Jay A Markwalder

Christine M Tarby

Ashok Vinayak Purandare

Tram N Huynh

Andres S Hernandez

Xiaopeng Sang

Guifen Zhang

Honghe Wan

Walter Lewis Johnson

Jennifer Inghrim

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Inhibitors of indoleamine 2,3-dioxygenase (IDO)

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Dihydropyrazole GPR40 modulators

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I). 

IDO inhibitors

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Imidazotriazinecarbonitriles useful as kinase inhibitors

Growing community of inventors

Lambertville, NJ, United States of America

Bin Chen